STOCK TITAN

Galmed Pharmaceuticals Ltd - GLMD STOCK NEWS

Welcome to our dedicated news page for Galmed Pharmaceuticals (Ticker: GLMD), a resource for investors and traders seeking the latest updates and insights on Galmed Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Galmed Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Galmed Pharmaceuticals's position in the market.

Rhea-AI Summary
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) announced a delay of at least 6 months in the initiation of its Primary Sclerosing Cholangitis (PSC) Ph 2a Study. The delay is due to unexpected events, resulting in a disruption of work, and a subsequent estimation of a 6-9 month delay. Galmed had planned to complete a Ph1 pharmacokinetic (PK) study to determine the bioavailability of its lead compound, Aramchol meglumine, for the treatment of PSC. The company is working with local and international partners to mitigate the delays and will continue to update as soon as practical.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.05%
Tags
clinical trial
-
Rhea-AI Summary
Galmed Pharmaceuticals announces allowance of Japanese patent for treatment of pulmonary and dermal fibrosis, strengthening patent protection for lead compound Aramchol until November 2037. Pre-clinical model shows significant anti-fibrotic effects of Aramchol. CEO highlights potential for Aramchol in treating various fibrotic indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
none
-
Rhea-AI Summary
Galmed Pharmaceuticals received a letter from Nasdaq indicating non-compliance with minimum bid price requirement. The company has 180 days to regain compliance by maintaining a minimum bid price of $1 for 10 consecutive days. Failure to do so may result in delisting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Galmed Pharmaceuticals Ltd. has entered into securities purchase agreements with two institutional investors to purchase 5,600,000 of its ordinary shares and warrants to purchase 5,600,000 ordinary shares at a combined purchase price of $1.25 per ordinary share and accompanying warrant, expected to raise approximately $7.0 million in gross proceeds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.29%
Tags
offering
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.91%
Tags
clinical trial AI
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.28%
Tags
none
Galmed Pharmaceuticals Ltd

Nasdaq:GLMD

GLMD Rankings

GLMD Stock Data

1.54M
3.51M
5.8%
14.16%
0.29%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
16 Zeev Tyomkin St 4th Fl

About GLMD

galmed pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or fabacs. aramchol is initially being developed for treating non-alcoholic steato-hepatitis, or nash, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. galmed pharmaceuticals galmed’s business has been, in its current legal structure, was incorporated in israel on july 31, 2013 as a privately held company. however, operating since 2000 under a different group of companies established in the same year. galmed was co-founded by professor tuvia gilat and allen baharaff, based on professor gilat’s extensive research in fabac’s and nash.